Navigation Links
Microbix And Hunan Biopharmaceutical To Build Asia's Largest Influenza Vaccine Facility
Date:10/27/2009

least 60 percent of their populations.

Gastle added, "This facility will make China an important source of influenza vaccine in the Asia region as well as offering significant capacity for the Chinese market which is growing significantly. In five years, the China market is expected to demand up to 500 million influenza vaccine doses annually."

The Microbix-Hunan project brings government ownership into the global vaccine industry at a technological level not previously achieved in China. A substantial investment is being made by Hunan in transferring the land to the joint venture and building the facility through the first phase of financing. As the project progresses, Hunan has agreed to provide additional funding through debt and has guaranteed the purchase of 100 million influenza vaccine doses. On all vaccine produced at the facility, Microbix will receive royalty payments and hold exclusive marketing rights outside of China.

The quality of the vaccine manufactured at the Microbix-Hunan facility will enable it to seek approval by the U.S. Food and Drug Administration and European Medicines Agency.

Mr. He Jihua, Deputy Mayor of Changsha Municipal Government, said, "We believe we have ensured the success of this important public health initiative by choosing Microbix as our partner. They bring expertise in developing vaccine and virology technologies, manufacturing and product distribution. The established collaboration that Microbix holds with world class biomedical and public health organizations will be invaluable."

He also said that "the cooperation between the two countries, Canada and China, and the two companies, Microbix and Hunan Biopharmaceutical in building this vaccine facility will bring greater vaccine capacity and improved health to China and other regions worldwide."

Microbix CEO William J. Gastle and Changsha National Bioindustry Park Deputy Director, Mr. Chen Zhigao, signed the ag
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
7. Microbix Sales Grow 22% For Nine Months
8. Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from Beijing ... half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from ... combines students from both universities and is taught on both continents. , “Our ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... ARUP Laboratories, pathologist, Ronald L. Weiss, MD, MBA, ... of American Pathologists at CAP ,11, the organization,s annual ... the CAP, the award honors members "who have made ... the specialty of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ...
... BEACH, Fla., Nov. 9, 2011 Biotech developer Divine ... which has been expanding the topical hair-growth segment, is ... system, Polaris API Solution 9, to be supplied by ... With well-established materials like minoxidil sulfate, finasteride, alfatradiol, ...
... Nov. 9, 2011 Third Quarter Highlights ... Awarded $5.7 million contract from Department of Defense (DoD) for ... awarded PharmAthene 50% net profit split on worldwide sales of ... million in net profits Completed 1500L commercial scale-up and ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 2Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 2PharmAthene Reports Third Quarter 2011 Financial and Operating Results 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 4PharmAthene Reports Third Quarter 2011 Financial and Operating Results 5PharmAthene Reports Third Quarter 2011 Financial and Operating Results 6PharmAthene Reports Third Quarter 2011 Financial and Operating Results 7PharmAthene Reports Third Quarter 2011 Financial and Operating Results 8
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... , Oct. 21, 2013   Arcturus Therapeutics, Inc. , an industry ... today announced it has secured $5 million in a Series A ... Canada , Japan and ... http://photos.prnewswire.com/prnh/20130531/MM24393LOGO ) The Series A funding, which comprised ...
... MA In a biological quirk that promises to ... potentially treating Fragile X syndrome, scientists at the University ... out a gene important for messenger RNA (mRNA) translation ... in a mouse model of a prevalent human neurological ...
... Jude Children,s Research Hospital scientists has linked an inherited ... developing a pediatric acute lymphoblastic leukemia (ALL) subtype that ... today in the online edition of the scientific journal ... found in the GATA3 gene. Researchers reported the high-risk ...
Cached Biology News:Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 2Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014 32 genetic wrongs make a biochemical right 22 genetic wrongs make a biochemical right 32 genetic wrongs make a biochemical right 4Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 2Inherited gene variation tied to high-risk pediatric leukemia and greater risk of relapse 3
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... array sample elements. , ,Includes: , DiscoverLight ... BSA in PBS (10X): 50 ml , ... , BupH Phosphate Buffered Saline: 8 packs ... ml ampules , SuperSignal West Pico Luminol Enhancer: 2 ...
Biology Products: